6 completed, 4 terminated, 2 unknown, 1 recruiting. 14 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Terminated 4, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
Follow Depsipeptides: new trials by email Literature Review of Depsipeptides trials Research Report on Depsipeptides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Laboratory Biomarker Analysis, Romidepsin, Venetoclax - Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 12 | 2018-09-11 | 2026-10-29 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Romidepsin, Abraxane - HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 9 | 2014-04-01 | 2025-05-16 |
| Trial of Romidepsin and Bortezomib for Multiple Myeloma Bortezomib, Romidepsin - Multiple Myeloma | Phase 2 | Terminated | Celgene | 32 | 2008-09-01 | 2019-11-25 |
| A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma Romidepsin - Peripheral T-cell Lymphoma | Phase 2 | Completed | Celgene | 131 | 2007-06-19 | 2020-02-11 |
| A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma depsipeptide, bortezomib, dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 40 | 2006-11-01 | 2011-08-12 |
| FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Depsipeptide - Malignant Melanoma, Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 4 | 2005-10-04 | 2023-06-28 |
| FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer depsipeptide - Ovarian Cancer | Phase 2 | Withdrawn | University of Chicago | 2005-05-01 | 2013-09-05 | |
| FR901228 in Treating Patients With Recurrent High-Grade Gliomas depsipeptide - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2005-01-01 | 2017-01-02 |
| A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) romidepsin (depsipeptide, FK228) - Cutaneous T-cell Lymphoma | Phase 2 | Completed | Celgene | 102 | 2005-01-01 | 2019-10-30 |
| S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Depsipeptide - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2004-06-01 | 2012-11-02 |
| A Research Study for Patients With Prostate Cancer Romidepsin - Prostate Cancer, Metastases | Phase 2 | Completed | Celgene | 35 | 2003-05-07 | 2019-11-18 |
| A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Depsipeptide - Peripheral T Cell Lymphoma (PTCL) | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 8 | 2006-03-06 |
Lymphoma, T-Cell (4) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell, Cutaneous (2) · Lymphoma, T-Cell, Peripheral (2) · Multiple Myeloma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Glioblastoma (1) · Gliosarcoma (1) · Immunoblastic Lymphadenopathy (1) · Inflammatory Breast Neoplasms (1) · Melanoma (1)
Celgene (4) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Peter MacCallum Cancer Centre, Australia (1) · Royal Marsden NHS Foundation Trust (1) · SWOG Cancer Research Network (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1) · University of Virginia (1)
United States (9) · Australia (2) · France (2) · Germany (2) · Poland (2) · United Kingdom (2) · Czechia (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1)
Daniel P. Petrylak, MD (1) · David H. Lawson, MD (1) · Dr Johann De Bono (1) · Enrica Marchi, M.D., PhD (1) · Gini Fleming, MD (1) · Howard Fine, MD (1) · Jasmine M Zain (1) · Jean Nichols, Ph.D. (1) · Maysa Abu-khalaf, MD (1) · Miles Prince, MD (1) · Myron Czuczman, MD (1) · Simon J Harrison, MBBS, PhD. (1) · Swaminathan P Iyer, MD (1) · Tina Neilson (1)
PMID 20697094, PMID 21377994, PMID 21911830, PMID 22271479, PMID 24456586, PMID 25279222, PMID 25605745, PMID 26965915
P30CA033572 (1), U01CA062399 (1), U10CA021115 (1), U10CA032102 (1)